Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.53 |
| ▸ | CA2 | P00918 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.42 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.42 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | PPARD | Q03181 | 1/20 | 0.42 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.42 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.42 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.42 |
| ▸ | MME | P08473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL197377 | 1.00 | NOD1 (0.53) | NOD1CA2MAPK1HDAC2CA1 | |
| SCHEMBL198715 | 1.00 | NOD1 (0.53) | NOD1CA2MAPK1HDAC2CA1 | |
| SCHEMBL11057343 | 0.93 | NOD1 (0.56) | NOD1GPR84FFAR1SLC1A2SLC1A1 | |
| Sulfuric Acid SCHEMBL5549277 | 0.92 | NOD1 (0.47) | NOD1CA2MAPK1HDAC2CA1 | |
| SCHEMBL7100031 | 0.91 | NOD1 (0.59) | NOD1GPR84FFAR1MAPTLCK | |
| SCHEMBL617558 | 0.86 | — | — | |
| SCHEMBL1604327 | 0.86 | — | — | |
| SCHEMBL2172011 | 0.86 | — | — | |
| SCHEMBL6238817 | 0.84 | CA2 (0.52) | NOD1CA2MAPK1HDAC2CA1 | |
| Butane SCHEMBL15570208 | 0.84 | HDAC1 (0.48) | NOD1CA2MAPK1HDAC2GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1105416-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | Keystone Biomedical, Inc. (US) | 2001-06-13 | — | — | EP | claimed |
| US-6063919-A | ESTERIFICATION OF O-DEPROTECTED DIBENZYL EXOCHELIC ACID WITH BENZYL EPI-COBACTIN, HYDROGENOLYTICALLY REMOVING THE THREE BENZYL GROUPS TO FORM EXOCHELIN 786SM(R) | KEYSTONE BIOMEDICAL, INC. (US) | 2000-05-16 | — | — | US | claimed |
| WO-2000009547-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF EXOCHELINS | KEYSTONE BIOMEDICAL, INC. (US) | 2000-02-24 | — | — | WO | claimed |
| US-20260048158-A1 | B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF | AKTIS ONCOLOGY INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-12427212-B2 | Nectin-4 binding miniproteins, conjugates and uses thereof | AKTIS ONCOLOGY, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250288704-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | Technische Universität München (DE) | 2025-09-18 | — | — | US | disclosed |
| US-20250242065-A1 | MINIPROTEINS, CONJUGATES & USES THEREOF | AKTIS ONCOLOGY, INC. | 2025-07-31 | — | — | US | disclosed |
| US-20250223627-A1 | FLUOROGENIC SUBSTRATES FOR AMINOPEPTIDASE DETECTION IN BIOFLUIDS | Sunbird Bio, Inc. | 2025-07-10 | — | — | US | disclosed |
| WO-2025122976-A1 | B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF | AKTIS ONCOLOGY, INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| US-20250003968-A1 | ACTIVITY-BASED CELL SORTING | HOWARD HUGHES MEDICAL INSTITUTE | 2025-01-02 | — | — | US | disclosed |
| CN-117042812-A | CXCR 4-ligands and precursors thereof for diagnostic and therapeutic uses | 慕尼黑工业大学 | 2023-11-10 | — | — | CN | disclosed |
| WO-1997038705-A1 | N-FORMYL HYDROXYLAMINE CONTAINING COMPOUNDS USEFUL AS ACE INHIBITORS AND/OR NEP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-10-23 | — | — | WO | disclosed |
| US-5616775-A | ESTERIFYING A N-PROTECTED METHIONINE; OXIDIZING; REACTING WITH AN ACID ANHYDRIDE THEN AN ALKALI METAL HYDROXIDE | BRISTOL-MYERS SQUIBB CO. (US) | 1997-04-01 | — | — | US | disclosed |
| EP-0759917-A1 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | GILEAD SCIENCES, INC. (US) | 1997-03-05 | — | — | EP | disclosed |
| WO-1996026933-A9 | NOVEL SELECTIVE INHIBITORS OF VIRAL OR BACTERIAL NEURAMINIDASES | — | 1996-11-28 | — | — | WO | disclosed |
| WO-1996023801-A2 | NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME | GILEAD SCIENCES, INC. (US) | 1996-08-08 | — | — | WO | disclosed |
| EP-0719273-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | disclosed |
| WO-1995007920-A1 | NUCLEOTIDE ANALOGS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | disclosed |
| EP-0640617-A1 | Substituted azepino (2,1-a)isoquinoline compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-03-01 | — | — | EP | disclosed |
| US-5362727-A | Treatment of cardiovascular disorders | BRISTOL-MYERS SQUIBB (US) | 1994-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242065-A1 | MINIPROTEINS, CONJUGATES & USES THEREOF | NECTIN4, CD2BP2, HAVCR2 | NOD1 2328/4885CA2 4494/4885MAPK1 4681/4885 |
| US-12427212-B2 | Nectin-4 binding miniproteins, conjugates and uses thereof | NECTIN4, CD2BP2, HAVCR2 | NOD1 1518/4885CA2 4457/4885MAPK1 4300/4885 |
| US-20250288704-A1 | CXCR4-LIGANDS FOR DIAGNOSTIC AND THERAPEUTIC USE AND PRECURSORS THEREOF | CXCR4, CXCR1, CXCR3 | NOD1 226/4885CA2 829/4885MAPK1 970/4885 |
| US-20260048158-A1 | B7-H3 MINIPROTEINS, CONJUGATES, AND USES THEREOF | MICA, CD274, JMJD6 | NOD1 3318/4885CA2 4630/4885MAPK1 3759/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.